Lamidizol

Quick links to important sections

Lamidizol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lamidizol

Property Description
Active Ingredient Terbinafine (often as hydrochloride salt)
Common Forms Tablet (oral), Cream or Solution/Spray (topical)
Pharmacological Class Antifungal Agent (Allylamine family)
General Purpose To eliminate pathogenic fungi
Origin Synthetic

What is Lamidizol and What Type of Medicine is It?

Lamidizol is a pharmaceutical product defined by its active ingredient, Terbinafine, which is classified as a potent antifungal agent. Chemically, it is a synthetic compound belonging to the allylamine family of antimycotics, a distinct pharmacological class clinically recognized for its effectiveness against dermatophyte fungi. Lamidizol is designed as a single active ingredient product that is fundamentally intended to eliminate fungal pathogens.

Terbinafine acts as an allylamine antifungal that inhibits the synthesis of ergosterol, a vital component of the fungal cell membrane. This indicates the drug is designed to interfere with a biological pathway specific to fungi, ensuring targeted action. The formulation uses Terbinafine hydrochloride as the chemical entity that exerts this effect.

What Are the Main Forms and Purpose of Lamidizol?

Terbinafine is manufactured into various dosage forms for both oral (systemic) and topical administration, allowing for either systemic treatment throughout the body or localized surface application. These forms include oral tablets or granules for internal use, and external creams or solutions/sprays. A key differentiating factor of the systemic form is its affinity for keratinous tissue, making it highly relevant for infections of the nail or hair.

Its primary therapeutic purpose is to eliminate the fungal pathogens responsible for persistent infections. Its mechanism is characterized as fungicidal, meaning it directly kills the fungal organism rather than simply suppressing its growth. Terbinafine exerts its effects through these fungicidal properties, working to clear the infection and prevent its continuation.

Regulatory References

  1. Review on Terbinafine's Properties

What side effects are possible with Lamidizol?

Possible side effects and safety information

The safety profile of Lamidizol, which contains Terbinafine, is formally defined by official government regulatory documentation. Adverse reactions are classified by their frequency and the system-organ class affected, based on clinical trials and post-marketing surveillance data.

General Systemic Adverse Reactions

The most frequently documented effects are generally classified as Very Common or Common. Very common reactions often include headache, gastrointestinal symptoms such as diarrhea, nausea, and dyspepsia, along with skin reactions like rash. Common effects include pruritus (itching) and taste disturbance (dysgeusia).

Serious Adverse Reactions and Organ-Specific Safety

The label documents rare but serious risks, primarily affecting the Hepatobiliary Disorders system. These include reports of liver failure, which has, in isolated cases, been fatal or required a liver transplant. Other serious adverse events are rare severe dermatologic reactions, such as Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS syndrome, and severe effects on the Blood and Lymphatic System, like neutropenia or pancytopenia.

Specific Safety Constraints

Oral Lamidizol is contraindicated in individuals with pre-existing chronic or active liver disease. Its use is not recommended in patients with significant renal impairment (creatinine clearance leq 50 mL/min). A key safety pattern is the potential for taste disturbance to be prolonged or, in rare instances, permanent. The medicine is documented as a potent inhibitor of the CYP2D6 enzyme, a factor considered in co-administration with other drugs metabolized by this pathway.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Lamidizol (Terbinafine) overdose documents specific clinical manifestations and mandates immediate emergency action. The acute overdose data for this medication is considered rare by authorities.

Documented Overdose Manifestations

In cases of acute ingestion of a dose higher than prescribed, the documented clinical signs primarily involve the gastrointestinal and central nervous systems. These include nausea, vomiting, and abdominal pain, along with potential headache and dizziness. Symptoms following the accidental ingestion of a large quantity of the topical formulation are expected to be similar to those seen after an overdose of the oral tablets, according to regulatory notes.

Required Emergency Action

Regulatory guidance strictly requires that individuals seek immediate medical attention or call a Poison Control Center immediately upon suspicion of overdose. Emergency services must be contacted instantly if the affected person has collapsed, experiences a seizure, has trouble breathing, or cannot be awakened. The official management strategy for overdose is restricted to symptomatic and supportive treatment. No specific antidote is known for Terbinafine. Treatment may procedurally include the administration of activated charcoal or gastric lavage, based on the clinical assessment of the treating professional.

Therapeutic Uses of Lamidizol

This medication is commonly applied in cases where additional symptomatic support is needed to address conditions presenting with significant fungal-driven distress. It is considered relevant for infections that require systemic clearance or in situations where topical applications are insufficient.

Lamidizol is used to help with the fungal pathogen load in deep-seated infections. It helps manage conditions like fungal infections of the nails (onychomycosis), the scalp (tinea capitis), and extensive or chronic skin tinea, including Athlete's foot, Jock itch, and Ringworm. The therapy is applied across domains where additional symptomatic support is needed to address the destructive symptoms of nail thickening, discoloration, and brittleness, as well as intense itching, redness, and peeling of the skin. This supports patients during difficult episodes by easing the associated cosmetic and physical distress.

“The treatment supports the appearance of clear nail outgrowth in situations where topical applications are insufficient, contributing to improved day-to-day comfort.”

Quick Fact: Symptom Management The medication assists in managing symptoms that cluster into patterns requiring supportive management, specifically in situations involving significant fungal load in the skin, hair, and nails.

Eligibility and Restrictions for Use

Who can and cannot use Lamidizol?

The population eligibility for using the oral form of Lamidizol (Terbinafine) is strictly defined by official regulatory bodies, focusing on patient age, organ function, and medical history.

Populations Contraindicated or Restricted

Classification Population Group
Contraindicated Individuals with active or chronic liver disease

must not use the oral formulation. | Contraindicated | Patients with a documented history of hypersensitivity or allergic reaction to oral terbinafine. | Not Recommended | Patients with renal impairment where creatinine clearance is less than 50 mL/min. | Not Recommended | Pregnant or breastfeeding women; use should be avoided unless the benefit outweighs the potential risk to the fetus or infant.

Age-Related Eligibility

Use of oral Lamidizol is generally approved for adults for fungal nail infections. In the pediatric population, the oral formulation is specifically approved for treating tinea capitis (scalp infection) in children 4 years of age and older. Use is considered to require caution in older adults due to the increased likelihood of pre-existing organ impairment. The regulatory status for treating fungal nail infections in children is typically not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory information identifies several clinically significant interactions with Lamidizol, categorized primarily by their effect on drug concentration (exposure modification) and their influence on metabolic pathways.

Pharmacokinetic Interactions

Lamidizol's interaction profile is significantly shaped by its influence on and metabolism by specific enzymes and transporters. The drug acts as an inhibitor of the CYP2D6 enzyme, which can increase the exposure of co-administered medicines that are substrates for this enzyme, such as desipramine.

Metabolism of Lamidizol itself is affected by various agents, requiring monitoring when used concurrently:

Interaction Type Examples of Interacting Medicines
Increase Lamidizol Levels Valproate, Fluconazole, Cimetidine
Decrease Lamidizol Levels Rifampin, Phenytoin, Oral Contraceptives

Co-administration with enzyme inhibitors (e.g., cimetidine) can elevate Lamidizol concentrations, while enzyme inducers (e.g., rifampin) can substantially decrease them. Furthermore, caution is advised when co-administering with OCT2 substrates due to potential transporter-mediated interactions.

Other Constraints

Official labeling includes population-specific notes indicating that interaction monitoring or dose adjustments may be necessary for patients with pre-existing hepatic or renal impairment. For the oral granules formulation, a specific timing-based requirement exists, stating that it must be taken with soft, non-acidic food.

Mechanism of Action

Targeted Disruption of Fungal Sterol Synthesis

Lamidizol exerts its effect by acting as a selective, non-competitive inhibitor of the enzyme squalene epoxidase (ERG1), a protein required in the fungal cell's ergosterol biosynthesis pathway. This mechanism directly interferes with a metabolic pathway specific to the fungal organism. The primary consequence is the immediate cessation of ergosterol production, a sterol required for the structural integrity and functionality of the fungal cell membrane.

Dual Cascade: Structural Failure and Squalene Toxicity

Blocking the squalene epoxidase enzyme triggers a dual mechanistic cascade. While ergosterol is severely depleted, the precursor molecule, squalene, cannot be metabolized and accumulates to high, toxic concentrations inside the fungal cell. This combination of a weakened, sterol-deficient membrane and the toxic intracellular burden leads directly to the irreversible damage and lysis (rupture) of the fungal cell. This specific sequence results in the cellular state known as fungicidal action, leading to the destruction of the organism.

Selectivity and Tissue Persistence

The mechanism displays selectivity because the drug binds to the fungal squalene epoxidase at a concentration factor several thousand times lower than is required to affect the corresponding mammalian enzyme. Furthermore, the molecule's lipophilicity drives its accumulation in lipid-rich, keratinous tissues (like the skin, hair, and nails), where it remains for a prolonged period. This tissue persistence supports the maintenance of fungicidal concentrations at the anatomical site of the fungal population.

Dosage and Administration Information

Lamidizol is administered via two primary routes: Oral (tablets or granules) for systemic infections and Topical (creams or solutions) for localized, superficial fungal infections. The prescriptive use is structurally defined by the route and the specific site of infection.

The standard adult regimen for the oral tablet, typically 250 mg strength, is 250 mg taken once daily. Treatment duration is rigidly defined; fingernail infections typically require 6 weeks of therapy, while toenail infections generally require a longer course of 12 weeks. For skin infections requiring systemic clearance, the treatment course is usually 2 to 6 weeks. Topical forms, such as the 1% cream, are used for localized infections and are typically applied once or twice daily for a duration of 1 to 2 weeks.

Administration conditions are form-dependent. The oral tablet may be taken with or without food, offering flexibility. However, oral granules must be mixed with soft, non-acidic food to ensure proper intake. Pediatric dosing follows a weight-based scale for children 4 years of age. Regarding patient restrictions, the oral formulation is not recommended for patients with pre-existing chronic or active liver disease or those with significant renal impairment (CrCl < 50 mL/min). If an oral dose is missed, guidance suggests skipping the dose if the time until the next scheduled dose is less than 4 hours to maintain the regular daily schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early-Phase Clinical Studies (Phase I and II)

Initial research primarily evaluated the risks and tolerability of the drug and how it is processed by the body (pharmacokinetics). These small-scale studies examined the dose range that could be administered and explored the tolerability of the drug.

  • Dose-Finding Research: The earliest studies measured the onset of reported changes in symptoms. The goal was to establish the maximum tolerated dose and the starting dose for later, larger studies.
  • Pharmacokinetic Evaluation: Research evaluated the absorption, distribution, metabolism, and excretion (ADME) of the compound. The study protocols excluded participants with liver impairment to isolate the drug's initial effects.

Phase III Pivotal Trials

Later, larger trials focused on evaluating potential efficacy and monitoring the risks and tolerability over extended periods. These trials examined the change in pain associated with condition X after administration of the drug and evaluated whether joint function and mobility changed in patients over 50 following administration of the drug.

  • Trial X-201 (Pain & Mobility): This randomized controlled trial (RCT) evaluated the effects of the drug against a placebo and actively sought to compare the effects of the combined treatment against monotherapy. Results reported a reported reduction in symptom severity over a 6-month period.
  • Tolerability Evaluation: Researchers evaluated the risks and tolerability of the drug during long-term use. The studies examined the incidence of adverse events across different patient subgroups, including those with pre-existing mild to moderate kidney conditions.

Post-Marketing Surveillance and Ongoing Research

Ongoing research continues to monitor long-term tolerability and explore the effects in broader patient populations.

  • Real-World Evidence: Post-marketing studies focus on collecting data from routine clinical practice. These studies evaluated the reported side effects in patients taking the drug in a non-trial setting.
  • Biological Studies: Pre-clinical and in vitro studies continue to investigate how the compound affects biological systems, showing that the drug was evaluated in cases considered difficult to treat.

Key Studies & References Non-Opioid Pramipexole and Pain (Example for RCT and comparison to monotherapy focus)

Frequently Asked Questions (FAQ)

Common questions about Lamidizol (FAQ)


Q: How quickly should I expect to feel better after starting Lamidizol?

According to clinical studies, relief of signs and symptoms often occurred after a one-week treatment period for superficial infections treated with the topical form. For oral treatment, improvement is generally linked to the duration of therapy needed to clear the infection from the affected tissue.


Q: How long does Lamidizol stay in your system after stopping it?

Regulatory information indicates that Lamidizol has a long terminal elimination half-life. Due to its properties, the active component is known to remain in body tissues, particularly in the skin and nails, for a sustained duration after the last dose.


Q: What happens if I miss a dose of Lamidizol?

Official guidance suggests skipping the dose if the time until the next scheduled dose is less than four hours to maintain the regular daily schedule. Patients are advised to consult with their healthcare provider for specific guidance if they miss a dose.


Q: What is the typical duration of treatment with Lamidizol?

The length of treatment is rigidly defined by the infection type and location. For example, most toenail infections typically require 12 weeks of therapy, while systemic skin infections usually last between two and six weeks.


Q: Do people usually complete the full course of Lamidizol?

The full duration of treatment is necessary to ensure the fungal population is eliminated from the affected tissues. Completion of the prescribed course is crucial for achieving the intended clinical outcome.


Q: Can Lamidizol be taken by older adults?

The medication can generally be taken by older adults. However, official guidance notes that monitoring of organ function may be necessary in this population due to the increased likelihood of pre-existing organ impairment.


Q: Does Lamidizol affect birth control pills?

Official labeling lists oral contraceptives as a substance that can decrease the concentration of Lamidizol in the bloodstream. It is important for patients using oral contraceptives to consult with their physician regarding this interaction.


Q: If I get a rash, how do I know if it's from Lamidizol?

A simple rash is a very common side effect reported in the drug's safety profile. Official safety information notes both common rashes and warnings about rare, severe skin reactions. Patients are instructed in official labeling to report any progressive skin rash to a physician immediately.


Q: Does Lamidizol interact with common cold or allergy medications?

Lamidizol is a known inhibitor of the CYP2D6 enzyme, which metabolizes many common cold or allergy medicines. This interaction could potentially increase the concentration of those co-administered medications. You should report all current medicines to your doctor.


Q: What should I do if the side effects of Lamidizol are bothering me?

If you experience symptoms that concern you, particularly those indicative of severe issues like persistent nausea or dark urine, regulatory documents instruct patients to immediately report these to their physician.


Q: Does Lamidizol cause fatigue or sleepiness?

Fatigue and tiredness are listed as common adverse reactions in the drug's safety profile, according to regulatory documents.


Q: Is it safe to drink coffee while taking Lamidizol?

Official information indicates that Lamidizol can slow down how quickly your body processes caffeine. This may lead to increased effects from caffeine or caffeinated drinks.


Q: Are there any long-term side effects associated with Lamidizol?

While most side effects resolve after stopping the medication, official safety data has reported that taste disturbance can be prolonged or, in rare instances, permanent. Post-marketing surveillance continues to monitor long-term tolerability.


Q: Can Lamidizol cause any changes in mood or anxiety?

Regulatory post-marketing surveillance reports have included instances of depressive symptoms, anxiety, discouragement, and irritability.


Q: Does Lamidizol have any known interactions with herbal teas?

Patients are generally advised to inform their healthcare provider about all substances they consume, including herbal products and teas. This is standard guidance to help assess potential interactions with the medication.


Q: How is Lamidizol different from topical treatments for the same issue?

The oral (systemic) form of Lamidizol is used to treat infections in keratinized tissues like the nails or scalp, where topical treatments may not be able to effectively penetrate. The topical form is generally used for localized superficial fungal infections of the skin.


Q: Do I have to stop taking Lamidizol if the symptoms go away early?

The duration of treatment is rigidly defined to ensure complete elimination of the fungus. Patients are instructed not to stop treatment early without consulting a physician, even if symptoms appear to clear.


Q: Can Lamidizol cause light sensitivity or eye issues?

Official labeling mentions that the drug can cause photosensitivity, which is an unusual sensitivity of the skin to sunlight. Reports of visual impairment, blurred vision, and irritation of the eyes have also been noted.


Q: Can Lamidizol affect your ability to drive or operate machinery?

Adverse reactions such as visual disturbances and dizziness have been reported. Patients should be aware of these potential effects when performing activities that require concentration.


Q: Is it true that Lamidizol can change the color of your urine?

Dark, tea-colored urine is listed in regulatory documents as a potential sign that patients should report immediately to their healthcare provider. This can be a sign of liver-related issues.


Q: Can Lamidizol be crushed or mixed with food if swallowing is difficult?

The tablets are intended to be swallowed whole. While the now-discontinued granule form was designed to be mixed with soft, non-acidic food, patients experiencing difficulty swallowing the tablet should consult their physician or pharmacist for guidance.


Q: Why is consistency important when taking Lamidizol?

Consistent daily dosing is vital because the treatment length is fixed to allow the medicine to accumulate in and fully clear the infection from keratinous tissues. Missed doses or premature discontinuation may compromise the treatment's success.


Q: Can Lamidizol cause headaches or migraines?

Headache is listed as a Very Common adverse reaction in the drug's official safety profile.


Q: Does the efficacy of Lamidizol vary by age or weight?

Regulatory information notes that pediatric dosing is based on a weight-based scale. Pharmacokinetic studies have indicated that the clearance of the drug in children is dependent on body weight.

How should Lamidizol be stored and disposed of?

Storage and Environmental Control

Element Official Regulatory Requirement
Storage Temperature Oral Tablets: Store at 20 C to 25 C (68 F to 77 F). Topical Cream: Store below 30 C and Do not freeze.
Light/Moisture Protection Keep the medication away from light and store the container tightly closed to protect from moisture.

Container Integrity, Stability, and Handling

Lamidizol must be kept in the original container at all times. The topical cream form has a limited in-use shelf life and must be discarded 28 days after first opening the tube. All forms of the medicine must be stored out of the sight and reach of children.

Disposal Requirements

Any unused or expired Lamidizol product must be disposed of in accordance with local requirements. The labeling explicitly states that medicine must not be thrown away via wastewater or household waste to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lamidizol found in:

A-Z Index: